Literature DB >> 22425021

Prolonged elevation of cytokine levels after human acute ischaemic stroke with evidence of individual variability.

Jun Yan1, Judith M Greer, Pamela A McCombe.   

Abstract

There is inflammation at the site of pathology in acute ischaemic stroke. In humans there is also elevation of levels of circulating cytokines in the days after stroke. We have previously found increased level of circulating T cells for up to three weeks after stroke. We have now measured cytokine levels for up to three weeks after stroke, looking for evidence of ongoing immune changes after the acute injury. Blood was collected from healthy controls and from subjects with acute ischaemic stroke on day 1, week 1 and week 3 after onset. Levels of interleukin 6 (IL6), interleukin 10 (IL10) and transforming growth factor beta (TGF-β) were measured by ELISA. We compared the cytokine levels in males and females, and correlated levels with stroke type as classified by the Oxfordshire stroke classification and stroke severity assessed by the NIH Stroke Scale. In the total group, levels TGF-β were significantly elevated at day 1. In the total group, levels of IL-6 were significantly elevated at all time-points. Levels of IL-10 were significantly elevated at week 1. The finding of elevated cytokine levels gives further evidence of ongoing immune activation for up to 3 weeks after acute ischaemic stroke. There was only a modest effect of stroke severity on levels of IL-6. There was also variability among individuals.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22425021     DOI: 10.1016/j.jneuroim.2012.02.013

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

1.  Temporal profile of cerebrospinal fluid, plasma, and brain interleukin-6 after normothermic fluid-percussion brain injury: effect of secondary hypoxia.

Authors:  Katina Chatzipanteli; Elizabeth Vitarbo; Ofelia F Alonso; Helen M Bramlett; W Dalton Dietrich
Journal:  Ther Hypothermia Temp Manag       Date:  2012-12       Impact factor: 1.286

Review 2.  Systemic, local, and imaging biomarkers of brain injury: more needed, and better use of those already established?

Authors:  Keri L H Carpenter; Marek Czosnyka; Ibrahim Jalloh; Virginia F J Newcombe; Adel Helmy; Richard J Shannon; Karol P Budohoski; Angelos G Kolias; Peter J Kirkpatrick; Thomas Adrian Carpenter; David K Menon; Peter J Hutchinson
Journal:  Front Neurol       Date:  2015-02-18       Impact factor: 4.003

Review 3.  Rational modulation of the innate immune system for neuroprotection in ischemic stroke.

Authors:  Diana Amantea; Giuseppe Micieli; Cristina Tassorelli; María I Cuartero; Iván Ballesteros; Michelangelo Certo; María A Moro; Ignacio Lizasoain; Giacinto Bagetta
Journal:  Front Neurosci       Date:  2015-04-29       Impact factor: 4.677

Review 4.  Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke.

Authors:  Aldo Bonaventura; Luca Liberale; Alessandra Vecchié; Matteo Casula; Federico Carbone; Franco Dallegri; Fabrizio Montecucco
Journal:  Int J Mol Sci       Date:  2016-11-25       Impact factor: 5.923

5.  Serum and cerebrospinal fluid immune mediators in children with autistic disorder: a longitudinal study.

Authors:  Carlos A Pardo; Cristan A Farmer; Audrey Thurm; Fatma M Shebl; Jorjetta Ilieva; Simran Kalra; Susan Swedo
Journal:  Mol Autism       Date:  2017-01-05       Impact factor: 7.509

Review 6.  Inflammatory molecules might become both biomarkers and therapeutic targets for stroke management.

Authors:  Laura Ramiro; Alba Simats; Teresa García-Berrocoso; Joan Montaner
Journal:  Ther Adv Neurol Disord       Date:  2018-08-06       Impact factor: 6.570

Review 7.  Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles.

Authors:  Sylwia Dabrowska; Anna Andrzejewska; Barbara Lukomska; Miroslaw Janowski
Journal:  J Neuroinflammation       Date:  2019-09-12       Impact factor: 8.322

Review 8.  An evaluation of the recognised systemic inflammatory biomarkers of chronic sub-optimal inflammation provides evidence for inflammageing (IFA) during multiple sclerosis (MS).

Authors:  Christopher Bolton
Journal:  Immun Ageing       Date:  2021-04-14       Impact factor: 6.400

9.  Relevance of distinct monocyte subsets to clinical course of ischemic stroke patients.

Authors:  Muichi Kaito; Shin-Ichi Araya; Yuichiro Gondo; Michiyo Fujita; Naomi Minato; Megumi Nakanishi; Makoto Matsui
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.